Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Work In Process (2023 - 2024)

Ligand Pharmaceuticals' Work In Process history spans 2 years, with the latest figure at $3.9 million for Q4 2024.

For Q4 2024, Work In Process rose 1911.79% year-over-year to $3.9 million; the TTM value through Dec 2024 reached $3.9 million, up 1911.79%, while the annual FY2024 figure was $3.9 million, 1911.79% up from the prior year.
Work In Process for Q4 2024 was $3.9 million at Ligand Pharmaceuticals, up from $260000.0 in the prior quarter.
Across five years, Work In Process topped out at $3.9 million in Q4 2024 and bottomed at $195000.0 in Q4 2023.